戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 g chemotherapy requires at least 6 months of multidrug therapy.
2 but negative MIBI scans failed to respond to multidrug therapy.
3  combinations and shorter, safer regimens of multidrug therapy.
4                 Considering the downsides of multidrug therapies and the relevance of dipeptidyl pept
5  is investigated in preclinical monotherapy, multidrug therapy, and lesion penetration experiments to
6  between humans, weakening the rationale for multidrug therapy as necessary to suppress resistance.
7 f bedaquiline, the patients started standard multidrug therapy (as defined by the World Health Organi
8 In 1985, 5.3 million patients were receiving multidrug therapy; by 1991, this figure had decreased to
9 which owed much to WHO and the donors of the multidrug therapy components, prompted WHO in 1991 to se
10 bial treatment is effective with recommended multidrug therapy for 6 months for paucibacillary lepros
11 ibitors (NNRTIs) are important components of multidrug therapy for HIV-1.
12 icipants who had received dapsone as part of multidrug therapy for leprosy (39 participants with the
13                                     Standard multidrug therapy for leprosy may be associated with sev
14 notherapy can deliver efficacy comparable to multidrug therapy for M. avium disease without promoting
15               The patient was started on WHO multidrug therapy for paucibacillary leprosy along with
16 e in patients already receiving contemporary multidrug therapy for this disease, the use of digitalis
17     Early diagnostic efforts and advances in multidrug therapy have considerably prolonged the surviv
18               Widespread BCG vaccination and multidrug therapy have dramatically reduced worldwide le
19 fector action and potentially become part of multidrug therapy in the future.
20                                              Multidrug therapy increases the risk for drug-drug inter
21 th substantial morbidity, and standard daily multidrug therapy is difficult to tolerate.
22 e rates, even with treatment by the on-going multidrug therapy (MDT).
23 ation of bacilli that survive in the face of multidrug therapy or in the generation of multidrug-resi
24         No infected child treated early with multidrug therapy progressed to AIDS or died by 1 year,
25 K axis that can be effectively targeted with multidrug therapies, providing a potential strategy for
26 d control measures for treating leprosy with multidrug therapy should control the spread of drug-resi
27                                              Multidrug therapy suppressed plasma HIV RNA to undetecta
28       There is growing interest in designing multidrug therapies that leverage tradeoffs to combat re
29 , received a mean of 16.1 +/- 10.8 months of multidrug therapy that included EMB.
30 unction and/or proteinuria, lowering BP with multidrug therapy that is inclusive of pharmacologic mod
31                       With the prevalence of multidrug therapy, there is great potential for serious
32 rs focus on the design and implementation of multidrug therapies to target complementary cancer speci
33 ex granulomatous disease, requires long-term multidrug therapy to overcome tolerance, an epigenetic d
34 obal implementation of this highly effective multidrug therapy took about 15 years.
35 sy prevalence in Pakistan has declined since multidrug therapy was introduced in the 1980s.
36 uring pregnancy or birth to Zdv if effective multidrug therapy was not initiated.
37                Leprosy has been treated with multidrug therapy, which has been distributed for free a
38 oaches including lifestyle modifications and multidrug therapy will be required in most cases to opti
39 rmat, treatment of TB requires six months of multidrug therapy with a mixture of broad spectrum and m